Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
- Author
- John Marshall MD, Joleen Hubbard MD
- Published
- Wed 28 Apr 2021
- Episode Link
- https://oncologypodcast.simplecast.com/episodes/optimizing-the-timing-and-sequencing-of-regorafenib-and-tas-102-for-patients-with-metastatic-colorectal-cancer-DiNaXgck
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Key data supporting the clinical use of these agents
- Optimal sequencing and timing of use
- Dosing considerations
- Key adverse events
Presenters:
Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program: BITLY NEEDED
